Jump Financial’s Achilles Therapeutics ACHL Stock Holding History

Jump Financial’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,000	Closed	-$55K	–	1986
2021 Q4	$55K	Buy	+11,000	New	+$66.6K	﹤0.01%	1301

Other funds holding ACHL

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Jump Financial's ACHL Position: Q1 2022 in Review

Jump Financial sold out of Achilles Therapeutics (ACHL) in Q1 2022, closing a stake of 11,000 shares — an estimated $55K sold.

Jump Financial first reported a position in ACHL in Q4 2021 and held it in 1 quarter. The position peaked at $55K in Q4 2021. 25 funds tracked by Wall St. Rank hold ACHL as of Q1 2022.

Jump Financial reported no remaining Achilles Therapeutics position as of Q1 2022 after selling out during the quarter.
Jump Financial sold 11,000 Achilles Therapeutics shares in Q1 2022, an estimated $55K.
Jump Financial first reported a position in Achilles Therapeutics in Q4 2021 and held it in 1 quarter.
Jump Financial's Achilles Therapeutics position peaked at $55K in Q4 2021.
25 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.